Thermo Fisher Scientific Inc (TMO) — Stock Price, Financials & Analysis

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Key Statistics — TMO

  • Latest Close: $605.00
  • Market Cap: $223.70B
  • P/E Ratio (TTM): 32.5
  • EPS (TTM): $18.59
  • Dividend Yield: 31.00%
  • Beta: 0.85
  • 52-Week High: $643.99
  • 52-Week Low: $435.27
  • Profit Margin: 15.0%
  • Return on Equity: 13.5%
  • Debt to Equity: 80.6

Sector: Healthcare — Diagnostics & Research

Income Statement — TMO

  • 2022: Revenue $44.91B, Net Income $6.95B
  • 2023: Revenue $42.86B, Net Income $6.00B
  • 2024: Revenue $42.88B, Net Income $6.33B
  • 2025: Revenue $44.56B, Net Income $6.70B
“”Wednesday, August 12, 2026
Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay§RegretRT=max⁡i∑t=1Tuit−∑t=1TuattR_T = \max_i \sum_{t=1}^{T} u_i^t - \sum_{t=1}^{T} u_{a_t}^tRT​=maxi​∑t=1T​uit​−∑t=1T​uat​t​§LP Dualmin⁡y,ww    s.t.    Ay≤w⋅1\min_{y,w} w \;\; \text{s.t.} \;\; Ay \leq w \cdot \mathbf{1}miny,w​ws.t.Ay≤w⋅1§Payoffu1(i,j)=aij,    u2(i,j)=−aiju_1(i,j) = a_{ij}, \;\; u_2(i,j) = -a_{ij}u1​(i,j)=aij​,u2​(i,j)=−aij​§Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay
0∑×$0 sometimesAlpha v0.1.0

The Shounya

HomeScreenerHeatmapSectorsDividendsCompareWatchlistPortfolioChartTechnicalScannerEarningsCorrelationSector AnalysisInsidersCongressNewsLearnAboutStatus
← Home← ScreenerChart TerminalTechnical
TMOHealthcare

Thermo Fisher Scientific Inc — Healthcare · Diagnostics & Research

$605.00+5.31 (+0.89%)
Mkt Cap
$223.70B
P/E
32.5
EPS
$18.59
Beta
0.85
Yield
31.00%
52W Hi
$643.99
52W Lo
$435.27
Vol
2.3M

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Diagnostics & Research
Employees
125,000
HQ
Waltham, MA, United States
Web
thermofisher.com

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Top Executives

NameTitleTotal Pay
Mr. Marc N. CasperChairman & CEO$6.2M
Mr. Gianluca PettitiPresident, COO & President of Products and Technologies$2.4M
Mr. James R. MeyerSenior VP & CFO—
Mr. Joseph R. HolmesVP & Chief Accounting Officer—
Mr. Ryan J. SnyderSenior VP & Chief Information Officer—
Dr. Karen E. Nelson Ph.D.Chief Scientific Officer—
Mr. Rafael TejadaVice President of Investor Relations—
Mr. Thomas Bailey Shropshire Jr.Senior VP and General Counsel—
Ms. Sandy B. PoundVP & Chief Communications Officer—
Mr. Alan J. MalusSenior Vice President of Strategy & Corporate Development$1.8M

Financial Statements

✓
Profitable
All 4 periods
✓
Revenue Growing
+3.9% latest, 2/3 up
✓
Earnings Growing
+5.8% latest, 2/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
15.0% net margin

Thermo Fisher Scientific Inc

Healthcare \u00b7 Diagnostics & Research

Market Cap$223.70B
Trailing P/E32.5
Forward P/E22.0
EPS (trailing)$18.59
EPS (forward)$27.51
Gross Margin41.0%
Operating Margin18.8%
Profit Margin15.0%
Dividend Rate$1.88/share
Dividend Yield31.0%
Payout Ratio9.7%

Revenue & Net Income

2022 – 2025, Annual

Revenue

Net Income

Profit Margins

2022 – 2025, Annual

Earnings Per Share

2022 – 2025, Annual

Dividends

No dividend history available.

Price Ranges

52-Week
$435.27$643.99
Fwd P/E22.0
Avg Volume2.3M
Shares Out0.37B

Key Ratios

Gross Margin41.0%
Operating Margin18.8%
Profit Margin15.0%
ROE13.5%
ROA5.1%
P/B4.2
D/E80.58
Current Ratio1.55
Dividend Rate$1.88
Payout Ratio9.7%

Cash & Debt

Cash 9%Debt 91%
Total Cash$4.06B
Total Debt$42.55B
Net Cash$-38.48B
Free Cash Flow$6.24B
Operating CF$9.01B

Ratings Snapshot

2.7 / 5
P/E2/5(32.5)
P/B3/5(4.2)
ROE3/5(13.5)
ROA3/5(5.1)
D/E1/5(80.6)
Liquidity4/5(1.6)

Growth Pulse

Revenue Growth+10.5%
Earnings Growth+9.4%

Analyst Recommendations

0m
Buy (28 analysts)
3
19
6
Strong Buy: 3
Buy: 19
Hold: 6
Sell: 0
Strong Sell: 0
MonthStr BuyBuyHoldSellStr Sell
0m319600
-1m319600
-2m518600
-3m519300

Income Snapshot 2025

Revenue
$44.6B
Net Income
$6.7B
Gross Margin
40.9%
Net Margin
15.1%
Op. Income
$8.1B
EPS
$17.77

Balance Sheet

2021 – 2025, Annual
Debt / Equity0.74x
Owns more than it owes — healthy
Current Ratio1.89x
Can easily cover short-term bills
Net Debt$29.53B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$97.15B$53.01B$43.98B$8.52B$34.49B0.78x
2023$98.73B$51.88B$46.73B$8.08B$34.92B0.75x
2024$97.32B$47.65B$49.59B$4.01B$31.27B0.63x
2025$110.34B$56.81B$53.41B$9.85B$39.38B0.74x

Balance Sheet Snapshot 2025

Total Assets$110.34B
Total Liabilities$56.81B
Equity$53.41B
Retained Earnings$59.16B
Goodwill$49.36B
Long-Term Debt$35.85B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$9B$-2B$-3B$7B$-2B
2023$8B$-5B$-4B$7B$-1B
2024$9B$-6B$-7B$7B$-1B
2025$8B$-4B$2B$6B$-2B

Capital Allocation 2025

CapEx$1.52B
Dividends Paid$636.0M
Buybacks$3.00B
Debt Repaid$3.51B
Debt Issued$8.85B
Net Change Cash$5.57B

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Diagnostics & Research
Employees
125,000
HQ
Waltham, MA, United States
Web
thermofisher.com

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Top Executives

NameTitleTotal Pay
Mr. Marc N. CasperChairman & CEO$6.2M
Mr. Gianluca PettitiPresident, COO & President of Products and Technologies$2.4M
Mr. James R. MeyerSenior VP & CFO—
Mr. Joseph R. HolmesVP & Chief Accounting Officer—
Mr. Ryan J. SnyderSenior VP & Chief Information Officer—
Dr. Karen E. Nelson Ph.D.Chief Scientific Officer—
Mr. Rafael TejadaVice President of Investor Relations—
Mr. Thomas Bailey Shropshire Jr.Senior VP and General Counsel—
Ms. Sandy B. PoundVP & Chief Communications Officer—
Mr. Alan J. MalusSenior Vice President of Strategy & Corporate Development$1.8M

Price Ranges

52-Week
$435.27$643.99
Fwd P/E22.0
Avg Volume2.3M
Shares Out0.37B

Key Ratios

Gross Margin41.0%
Operating Margin18.8%
Profit Margin15.0%
ROE13.5%
ROA5.1%
P/B4.2
D/E80.58
Current Ratio1.55
Dividend Rate$1.88
Payout Ratio9.7%

Cash & Debt

Cash 9%Debt 91%
Total Cash$4.06B
Total Debt$42.55B
Net Cash$-38.48B
Free Cash Flow$6.24B
Operating CF$9.01B

Ratings Snapshot

2.7 / 5
P/E2/5(32.5)
P/B3/5(4.2)
ROE3/5(13.5)
ROA3/5(5.1)
D/E1/5(80.6)
Liquidity4/5(1.6)

Growth Pulse

Revenue Growth+10.5%
Earnings Growth+9.4%

Analyst Recommendations

0m
Buy (28 analysts)
3
19
6
Strong Buy: 3
Buy: 19
Hold: 6
Sell: 0
Strong Sell: 0
MonthStr BuyBuyHoldSellStr Sell
0m319600
-1m319600
-2m518600
-3m519300

Financial Statements

✓
Profitable
All 4 periods
✓
Revenue Growing
+3.9% latest, 2/3 up
✓
Earnings Growing
+5.8% latest, 2/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
15.0% net margin

Thermo Fisher Scientific Inc

Healthcare \u00b7 Diagnostics & Research

Market Cap$223.70B
Trailing P/E32.5
Forward P/E22.0
EPS (trailing)$18.59
EPS (forward)$27.51
Gross Margin41.0%
Operating Margin18.8%
Profit Margin15.0%
Dividend Rate$1.88/share
Dividend Yield31.0%
Payout Ratio9.7%

Revenue & Net Income

2022 – 2025, Annual

Revenue

Net Income

Profit Margins

2022 – 2025, Annual

Earnings Per Share

2022 – 2025, Annual

Dividends

No dividend history available.

Income Snapshot 2025

Revenue
$44.6B
Net Income
$6.7B
Gross Margin
40.9%
Net Margin
15.1%
Op. Income
$8.1B
EPS
$17.77

Balance Sheet

2021 – 2025, Annual
Debt / Equity0.74x
Owns more than it owes — healthy
Current Ratio1.89x
Can easily cover short-term bills
Net Debt$29.53B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$97.15B$53.01B$43.98B$8.52B$34.49B0.78x
2023$98.73B$51.88B$46.73B$8.08B$34.92B0.75x
2024$97.32B$47.65B$49.59B$4.01B$31.27B0.63x
2025$110.34B$56.81B$53.41B$9.85B$39.38B0.74x

Balance Sheet Snapshot 2025

Total Assets$110.34B
Total Liabilities$56.81B
Equity$53.41B
Retained Earnings$59.16B
Goodwill$49.36B
Long-Term Debt$35.85B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$9B$-2B$-3B$7B$-2B
2023$8B$-5B$-4B$7B$-1B
2024$9B$-6B$-7B$7B$-1B
2025$8B$-4B$2B$6B$-2B

Capital Allocation 2025

CapEx$1.52B
Dividends Paid$636.0M
Buybacks$3.00B
Debt Repaid$3.51B
Debt Issued$8.85B
Net Change Cash$5.57B
0∑×

Free market data & analysis tools.

Markets
HomeScreenerHeatmapSectorsEarnings
Tools
WatchlistCompareChart TerminalTechnical
Research
CongressInsidersDividendsCorrelation
© 2026 ShounyaAlpha v0.1.0Not financial advice · hanabira.org